BioCentury | Nov 6, 2017
Distillery Therapeutics

Neurology

...endosomal CRLR and NK1R inhibitors. Merck & Co. Inc. and Ono Pharmaceutical Co. Ltd. market Emend...
BioCentury | Jul 13, 2017
Targets & Mechanisms

Insider signaling

...Oral Risks Allergic reactions, diarrhea and other side effects associated with the marketed TACR1 inhibitors Emend...
...inhibitors are marketed for chemotherapy-induced nausea and vomiting (CINV): Merck & Co. Inc. ’s Emend fosaprepitant dimeglumine...
BioCentury | May 9, 2017
Distillery Therapeutics

Cancer

...Merck & Co. Inc. and Ono Pharmaceutical Co. Ltd. market oral and IV formulations of Emend...
BioCentury | Apr 4, 2016
Clinical News

Emend regulatory update

...Japan approved a regulatory application from Ono for IV Proemend fosaprepitant meglumine to include treatment of chemotherapy-induced...
...resulting from antineoplastic agents. Ono markets an oral formulation of the drug in Japan as Emend...
...Kenilworth, N.J. Product: Emend ( Ivemend - EU, Proemend ) fosaprepitant dimeglumine, fosaprepitant meglumine ( MK-0517 , ONO-7847...
BioCentury | Nov 2, 2015
Clinical News

Emend regulatory update

...EMA’s CHMP recommended approval of a label expansion for Emend from Merck to include patients ages...
...chemotherapy in patients ages >=12. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Emend ( Proemend...
BioCentury | Sep 14, 2015
Clinical News

Emend aprepitant regulatory update

...FDA approved an sNDA from Merck for Emend aprepitant to prevent chemotherapy-induced nausea and vomiting (CINV...
...nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Emend...
...to prevent postoperative nausea and vomiting (PONV). Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Emend...
BioCentury | Aug 10, 2015
Clinical News

Emend: Phase III data

...trial in 1,001 patients receiving moderately emetogenic chemotherapy showed that a single dose 150 mg Emend for Injection...
...starting chemotherapy), vs. placebo plus ondansetron and dexamethasone (78.9% vs. 68.5%, p<0.001). On secondary endpoints, Emend for Injection...
...Kenilworth, N.J. Product: Emend ( Ivemend - EU, Proemend ) fosaprepitant dimeglumine, fosaprepitant meglumine ( MK-0517 , ONO-7847...
BioCentury | Jun 8, 2015
Clinical News

Proemend fosaprepitant meglumine regulatory update

...Ono submitted a regulatory application in Japan for Proemend fosaprepitant meglumine to treat chemotherapy-induced nausea and vomiting...
...administration of antineoplastic agents. Ono markets an oral formulation of the drug in Japan as Emend...
...Whitehouse Station, N.J. Product: Proemend fosaprepitant meglumine ( Ivemend , Emend ) (fosaprepitant dimeglumine) ( MK-0517 , ONO-7847...
BioCentury | Jul 21, 2014
Clinical News

Emend aprepitant: Phase III data

...patients ages 6 months-17 years receiving moderately, highly or very highly emetogenic chemotherapy showed that Emend...
...Society of Oral Oncology meeting in Miami. Merck markets Emend capsules for oral use and Emend for injection...
...worldwide regulatory submissions for Emend will follow the U.S. submissions. Ono has Japanese rights to Emend...
BioCentury | Apr 7, 2014
Clinical News

Sustol: Phase III started

...guidelines (see BioCentury, April 1, 2013). Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) markets Emend...
Items per page:
1 - 10 of 45